Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States

Emerging Infectious Diseases

关键词: tuberculosis and other mycobacteria;    antimicrobial resistance;    drug monitoring;    bedaquiline;    pretomanid;    linezolid;   

DOI  :  10.3201/eid2701.203766

来源: DOAJ

【 摘 要 】

The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.

【 授权许可】

Unknown